Trial Profile
A Phase III, Open-labelled, Randomised Study of Neoadjuvant Docetaxel+Oxaliplatin+S-1 (DOS) + Surgery + Adjuvant S-1 Versus Surgery + Adjuvant S-1 in Patients With Resectable Advanced Gastric Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Oxaliplatin (Primary) ; Gimeracil/oteracil/tegafur
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms PRODIGY
- Sponsors Sanofi
- 20 Nov 2023 Status changed from active, no longer recruiting to completed.
- 06 Jun 2023 Results of long-term follow-up outcomes, including overall survival (OS), presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 13 Feb 2023 Planned End Date changed from 3 Jan 2023 to 31 Mar 2023.